4 clinical cases of patients in whom the combination of chondroitin and glucosamine should be considered Case report
Article Sidebar
Published:
Dec 31, 2021
Keywords:
osteoarthritis, SYSADOA, analgesic treatment
Main Article Content
Abstract
Osteoarthritis is a chronic disease that affects mainly the elderly. The primary form of therapy is analgesic pharmacotherapy in accordance with the analgesic ladder. Another, still controversial, method is the administration of symptomatic slow-acting drugs for osteoarthritis, the main advantage of which is that they are practically devoid of toxicity. A recent review of papers on the use of this group of drugs has shown that the most potent modifying effect has the combination of glucosamine and chondroitin, which synergistically change the metabolism of the articular cartilage. In this article, we present four clinical cases in which the combination of glucosamine and chondroitin was effective.
Article Details
How to Cite
Tłustochowicz, W., & Tłustochowicz , M. (2021). 4 clinical cases of patients in whom the combination of chondroitin and glucosamine should be considered. Medycyna Faktow (J EBM), 14(4(53), 444-449. https://doi.org/10.24292/01.MF.0421.15
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Managing osteoarthritis. NICE Pathway (access: 11.12.2020).
2. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
3. Kolasinski S, Neogi T, Hochberg M et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72(2): 149-62. http://doi.org/10.1002/acr.24131.
4. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390(10090): e21-33.
5. Kloppenburg M, Kroon FP, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
6. Bannuru R, Osani M, Vaysbrot E et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578-89.
7. Sharma L. Osteoarthritis of the Knee. N Engl J Med. 2021; 384: 51-9. http://doi.org/10.1056/NEJMcp1903768.
8. Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019; 37 suppl 120(5): 135-40.
9. Tłustochowicz W. Zastosowanie wolno działających leków objawowych w chorobie zwyrodnieniowej stawów. Skuteczność połączenia glukozaminy z chondroityną w świetle dowodów. Medycyna Faktów. 2021; 14(1): 110-7.
10. Forestier R, Forestier F, Francon A. Spa therapy and knee osteoarthritis: A systematic review. Ann Phys Reh Med. 2016, 56: 216-26.
11. Skou S, Roos E. Physical therapy for patients with knee and hip osteoarthritis: supervised, active treatment is current best practice Clin Exp Rheumatol. 2019; 37(suppl 120): S112-S117.
12. Lipiński M. Konsekwencje stosowania niewystarczających dawek inhibitorów pompy protonowej w gastroprotekcji – opis przypadku. Lekarz POZ. 2021; 7(1): 49-53.
13. Hochberg M, Martel-Pelletier J, Monfort J et al.; on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75(1): 37-44. http://doi.org/10.1136/annrheumdis-2014-206792.
14. Fransen M, Agaliotis M, Nairn L et al.; on behalf of the LEGS study collaborative group: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015; 74(5): 851-8. http://doi.org/10.1136/annrheumdis-2013-203954.
15. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086. http://doi.org/10.1136/bmj.c7086.
16. Schmidt M, Sørensen H, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018; 362: k3426. http://doi.org/10.1136/bmj.k3426.
17. Garriga C, Goff M, Paterson E et al. Clinical and molecular associations with outcomes at 2 years after acute knee injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK). Lancet Rheumatol. 2021. Published Online: June 24, 2021. http://doi.org/10.1016/S2665-9913(21)00116-8.
18. Atukorala I, Kwoh C, Guermazi A et al. Synovitis in knee osteoarthritis: a precursor of disease? Ann Rheum Dis. 2016; 75(2): 390-5.
19. Scanzello C, Plaas A, Crow M. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008; 20: 565-72.
20. Calamia V, Mateos J, Fernández-Puente P et al. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014; 4: 5069. http://doi.org/10.1038/srep05069.
2. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
3. Kolasinski S, Neogi T, Hochberg M et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72(2): 149-62. http://doi.org/10.1002/acr.24131.
4. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390(10090): e21-33.
5. Kloppenburg M, Kroon FP, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
6. Bannuru R, Osani M, Vaysbrot E et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578-89.
7. Sharma L. Osteoarthritis of the Knee. N Engl J Med. 2021; 384: 51-9. http://doi.org/10.1056/NEJMcp1903768.
8. Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019; 37 suppl 120(5): 135-40.
9. Tłustochowicz W. Zastosowanie wolno działających leków objawowych w chorobie zwyrodnieniowej stawów. Skuteczność połączenia glukozaminy z chondroityną w świetle dowodów. Medycyna Faktów. 2021; 14(1): 110-7.
10. Forestier R, Forestier F, Francon A. Spa therapy and knee osteoarthritis: A systematic review. Ann Phys Reh Med. 2016, 56: 216-26.
11. Skou S, Roos E. Physical therapy for patients with knee and hip osteoarthritis: supervised, active treatment is current best practice Clin Exp Rheumatol. 2019; 37(suppl 120): S112-S117.
12. Lipiński M. Konsekwencje stosowania niewystarczających dawek inhibitorów pompy protonowej w gastroprotekcji – opis przypadku. Lekarz POZ. 2021; 7(1): 49-53.
13. Hochberg M, Martel-Pelletier J, Monfort J et al.; on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75(1): 37-44. http://doi.org/10.1136/annrheumdis-2014-206792.
14. Fransen M, Agaliotis M, Nairn L et al.; on behalf of the LEGS study collaborative group: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015; 74(5): 851-8. http://doi.org/10.1136/annrheumdis-2013-203954.
15. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086. http://doi.org/10.1136/bmj.c7086.
16. Schmidt M, Sørensen H, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018; 362: k3426. http://doi.org/10.1136/bmj.k3426.
17. Garriga C, Goff M, Paterson E et al. Clinical and molecular associations with outcomes at 2 years after acute knee injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK). Lancet Rheumatol. 2021. Published Online: June 24, 2021. http://doi.org/10.1016/S2665-9913(21)00116-8.
18. Atukorala I, Kwoh C, Guermazi A et al. Synovitis in knee osteoarthritis: a precursor of disease? Ann Rheum Dis. 2016; 75(2): 390-5.
19. Scanzello C, Plaas A, Crow M. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008; 20: 565-72.
20. Calamia V, Mateos J, Fernández-Puente P et al. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014; 4: 5069. http://doi.org/10.1038/srep05069.